Cardiovascular Innovations and Applications,
Journal Year:
2024,
Volume and Issue:
9(1)
Published: Jan. 1, 2024
Vascular
diseases,
including
atherosclerosis,
aneurysms,
and
vascular
calcification,
are
a
leading
cause
of
morbidity
mortality
worldwide.
In
past
decades,
the
gut
microbiota
has
been
found
to
be
an
indispensable
population
exerting
effects
on
hosts
under
physiological
pathological
conditions.
Gut
microbiota-derived
metabolites,
such
as
trimethylamine-N-oxide
short-chain
fatty
acids,
mediate
these
by
regulating
cells
systematically.
Translation
research
knowledge
clinical
scenarios
led
development
new
therapies
dietary
interventions
metabolite
inhibitors.
This
review
describes
recent
advancements
in
understanding
interplay
between
dysfunction,
potential
treatments
for
diseases.
Applied Microbiology,
Journal Year:
2025,
Volume and Issue:
5(1), P. 29 - 29
Published: March 13, 2025
Atherosclerosis
(AS)
is
emerging
as
a
major
global
public
health
problem.
Researchers
are
developing
and
implementing
various
anti-AS
strategies.
This
study
aimed
to
investigate
gut
microbiota
metabolite
changes
associated
with
elevated
serum
low-density
lipoprotein
cholesterol
(LDL-c).
Mice
were
divided
into
two
equal
groups:
Group
C
(mice
from
healthy
subjects)
B
AS).
At
the
end
of
8-week
study,
blood
samples
collected
for
lipid
analysis;
rectal
feces
microbial
16S
rRNA
sequencing
analysis
metabolomics
analysis.
Our
results
showed
that
group
significantly
increased
levels
LDL-c.
However,
no
statistically
significant
differences
observed
in
richness
diversity
microbiota,
but
we
an
increase
ratio
Firmicutes
Bacteroidetes
abundance
Parabacteroides
Goldstein.
In
addition,
untargeted
metabolomic
fecal
revealed
128
metabolites
differentially
expressed
between
groups
B.
Notably,
was
found
have
involved
metabolism
pathways,
such
estrogen
glucuronide,
ginsenoside
f1,
Pe
(16:1e/14,15-epete),
prostaglandin
E1.
Those
data
highlight
importance
understanding
AS
perspective
establish
foundation
future
research
on
AS.
PeerJ,
Journal Year:
2025,
Volume and Issue:
13, P. e19223 - e19223
Published: April 15, 2025
Background
Irritable
bowel
syndrome
(IBS)
is
a
common
gastrointestinal
disorder
with
poorly
understood
mechanisms.
Variations
in
gut
microbiota
composition
are
observed
different
IBS
subtypes.
Ginsenosides
have
shown
potential
alleviating
symptoms,
but
their
interactions
subtypes
not
well
studied.
Methods
In
this
study,
we
investigated
the
effects
of
ginsenosides
on
both
healthy
participants
and
suffering
from
characterized
by
diarrhea
(IBS-D)
or
constipation
(IBS-C),
using
vitro
fermentation
alongside
16S
rRNA
sequencing
bioinformatics
analyses.
Results
The
analysis
demonstrated
that
there
were
no
statistically
significant
alterations
α-
β-diversity
between
ginsenosides-treated
control
groups
across
all
models.
However,
microbial
assessment
revealed
presence
51
shared
genera,
notable
variations
enrichment
specific
taxa.
Specifically,
LEfSe
that,
following
treatment,
model
exhibited
Stenotrophomonas
Achromobacter
,
while
IBS-D
Pseudomonas
.
Conclusions
results
elucidate
distinctive
signatures
associated
treatment
groups,
underscoring
therapeutic
efficacy
modulating
microbiota.
This
study
highlights
necessity
for
further
investigation
into
targeted
microbiome
therapies
IBS,
which
may
facilitate
development
more
personalized
efficacious
strategies
health.
The World Journal of Men s Health,
Journal Year:
2024,
Volume and Issue:
42(4), P. 772 - 772
Published: Jan. 1, 2024
Explore
the
causal
relationship
between
gut
microbiota
and
erectile
dysfunction
(ED)
at
phylum,
class,
order,
family,
genus
levels,
identify
specific
pathogenic
bacteria
that
may
be
associated
with
onset
progression
of
ED.
Cardiovascular Innovations and Applications,
Journal Year:
2024,
Volume and Issue:
9(1)
Published: Jan. 1, 2024
Vascular
diseases,
including
atherosclerosis,
aneurysms,
and
vascular
calcification,
are
a
leading
cause
of
morbidity
mortality
worldwide.
In
past
decades,
the
gut
microbiota
has
been
found
to
be
an
indispensable
population
exerting
effects
on
hosts
under
physiological
pathological
conditions.
Gut
microbiota-derived
metabolites,
such
as
trimethylamine-N-oxide
short-chain
fatty
acids,
mediate
these
by
regulating
cells
systematically.
Translation
research
knowledge
clinical
scenarios
led
development
new
therapies
dietary
interventions
metabolite
inhibitors.
This
review
describes
recent
advancements
in
understanding
interplay
between
dysfunction,
potential
treatments
for
diseases.
